Colin A. Baron, MBAAffiliate Consultant

Areas of Expertise
  • Genomics Discovery & Transnational Research
  • Commercial Strategy & Marketing
  • Bioinformatics Analysis
  • MBA
  • Bachelors, Microbiology & Economics

Drawing on over 15 years experience in genomics discovery and translational research, Colin co-founded Chrysalis Biomedical Advisors in 2016. Prior to Chrysalis, Colin served as Senior Director, Head of Global Product Management at QIAGEN  and was responsible for driving development, commercial strategy, and marketing for Next Generation Sequencing and Single Cell platforms.

Previously, Colin held numerous positions at Illumina, joining the former Solexa team shortly after its acquisition. During his 6-year tenure, he managed the company’s NGS sequencing chemistry portfolio and led over 35 major sequencing platform launches, ranging from the the Genome Analyzer II to the NextSeq and HiSeq X10 systems. He also designed and developed Clinical & Translational products for Illumina’s BeadXpress Diagnostic platform, as well as Illumina’s premium line of LDT-focused sequencing products

Prior to Illumina, Colin held several Academic Core Lab management positions at UC Davis, including bioinformatics analysis and clinical tissue and serum biobanking for an NCI-designated Biobank. Colin graduated from UC Davis in 2001 with a double major in Microbiology and Economics.  He earned his MBA from the UC Davis Graduate School of Management in 2008.

Colin is an avid traveler, enjoys British dramatic theatre, and loves having his German pronunciation corrected by his 3 year old son.